Biopure Announces 2008 First Quarter Financi...(cology clinical nursespecialist is worki...)

Investor Relations Firm Appointed

Biopure has appointed Sharon Merrill Associates, Inc. as its strategic communications firm to support its investor relations and corporate communications efforts. Sharon Merrill Associates is based in Boston.

Accounting Firm

Ernst & Young LLP has advised Biopure that they are not standing for reappointment for the fiscal year 2008 audit.

FDA Workshop

The U.S. FDA has announced a public workshop entitled: Hemoglobin Based Oxygen Carriers: Current Status and Future Directions, on April 29 and 30, 2008. Biopure has been asked to present at the workshop.

South Africa

Usage of Hemopure in South Africa is continuing to increase.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 197,000 units of Oxyglobin since it first began to mar
'/>"/>